MAPT and Alzheimer disease: Although some positive news on potential new therapies including Aducanumab targeting Aβ or anti‐Tau antibodies have raised some hope (Vaz & Silvestre, 2020), the need for understanding the mechanisms of neuronal death in AD for finding more effective therapies retains its utmost priority.